NovaBridge Biosciences (NBP) Total Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Total Liabilities for 8 consecutive years, with $29.6 million the latest figure, recorded in Q4 2025.

• Quarterly Total Liabilities rose 156.78% year-over-year to $29.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.6 million (up 156.78% YoY) and the FY2025 annual result came in at $29.6 million, up 156.78% from the prior year.
• Total Liabilities advanced to $29.6 million in Q4 2025 per NBP's latest filing, from $18.5 million in the prior quarter.
• Over the last five years, Total Liabilities for NBP reached as high as $163.6 million in Q4 2022 and fell as low as $10.0 million in Q2 2025.
• A 5-year average of $74.0 million and a median of $29.6 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities slumped 90.73% — and 2025, when it jumped 156.78%.
• Year by year, Total Liabilities stood at $162.9 million in 2021, then grew by 0.43% to $163.6 million in 2022, then decreased by 24.05% to $124.3 million in 2023, then plunged by 90.73% to $11.5 million in 2024, then surged by 156.78% to $29.6 million in 2025.
• According to Business Quant data, Total Liabilities over the past three periods registered $29.6 million, $18.5 million, and $10.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.